Эффективность и безопасность квадротерапии без препаратов висмута при лечении пациентов с Helicobacter pylori-ассоциированной язвенной болезнью желудка и двенадцатиперстной кишки
Эффективность и безопасность квадротерапии без препаратов висмута при лечении пациентов с Helicobacter pylori-ассоциированной язвенной болезнью желудка и двенадцатиперстной кишки
Велиев А.М., Маев И.В., Андреев Д.Н. и др. Эффективность и безопасность квадротерапии без препаратов висмута при лечении пациентов с Helicobacter pylori-ассоциированной язвенной болезнью желудка и двенадцатиперстной кишки. Терапевтический архив. 2019;91(8): 28–33. DOI: 10.26442/00403660.2019.08.000382
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Оценка эффективности и безопасности квадротерапии без препаратов висмута (одномоментная терапия) у пациентов с Helicobacter pylori-ассоциированной язвенной болезнью желудка и двенадцатиперстной кишки в рамках сравнительного исследования в российской популяции пациентов.
Материалы и методы. Проведено проспективное рандомизированное исследование, в которое включено 210 пациентов с неосложненной H. pylori-ассоциированной язвенной болезнью желудка/двенадцатиперстной кишки. В процессе рандомизации пациенты разделены на три равные группы (n=70) в зависимости от назначаемой 10-дневной схемы эрадикационной терапии (ЭТ): первая группа получала классическую тройную схему (омепразол 20 мг 2 раза в день, амоксициллин 1000 мг 2 раза в день и кларитромицин 500 мг 2 раза в день); вторая группа получала квадротерапию с препаратами висмута (омепразол 20 мг 2 раза в день, тетрациклин 500 мг 4 раза в день, метронидазол 500 мг 3 раза в день, висмута трикалия дицитрат 120 мг 4 раза в день); третья группа получала квадротерапию без препаратов висмута (омепразол 20 мг 2 раза в день, амоксициллин 1000 мг 2 раза в день, кларитромицин 500 мг 2 раза в день и метронидазол 500 мг 2 раза в день). Диагностика инфекции H. pylori при скрининге и контроле эрадикации осуществлялась при помощи быстрого уреазного теста биоптата и дыхательной тест-системы. Контроль эффективности ЭТ микроорганизма производился не ранее чем через 4 нед после проведенного лечения. На протяжении курса терапии проводилась оценка частоты развития побочных явлений при помощи специального опросника.
Результаты и обсуждение. Эффективность тройной терапии составила 72,8% (ITT; 95% ДИ 62,17–83,54) и 78,4% (PP; 95% ДИ 68,19–88,72); квадротерапии с препаратом висмута – 80,0% (ITT; 95% ДИ 70,39–89,6) и 84,8% (PP; 95% ДИ 75,96–93,73); квадротерапии без препарата висмута – 84,2% (ITT; 95% ДИ 75,54–93,02) и 92,1% (PP; 95% ДИ 85,43–98,94). Квадротерапия без препарата висмута оказалась достоверно эффективнее классической тройной терапии в выборке PP (p=0,044883). При статистическом анализе отмечались тенденции к снижению эффективности ЭТ у пациентов, использовавших антибиотикотерапию в анамнезе (ОШ 0,4317; 95% ДИ 0,1776–1,049), и у лиц с генотипом быстрого метаболизма – CYP2C19*1/*1 (ОШ 0,12; 95% ДИ 0,005848–2,4624). Частота побочных явлений при применении тройной терапии составила 18,5% (95% ДИ 9,23–27,91), при использовании квадротерапии с препаратом висмута – 20,0% (95% ДИ 10,39–29,6), а при применении квадротерапии без препаратов висмута – 24,2% (95% ДИ 13,98–34,58).
Заключение. Проведенное проспективное рандомизированное исследование продемонстрировало высокую эффективность квадротерапии без препарата висмута в рамках эрадикации инфекции H. pylori у российского контингента пациентов.
Ключевые слова: Helicobacter pylori, эрадикационная терапия, квадротерапия без препарата висмута, одномоментная терапия.
Materials and methods. A prospective randomized trial was conducted, which included 210 patients with H. pylori-associated gastric/duodenal ulcer without complications. During the process of randomization, the patients were divided into three equal groups (n=70) depending on the prescribed 10-day scheme of eradication therapy (ET): the first group received the classic triple scheme (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day and Clarithromycin 500 mg 2 times a day); the second group received quadruple therapy with bismuth drugs (Omeprazole 20 mg 2 times a day, Tetracycline 500 mg 4 times a day, Metronidazole 500 mg 3 times a day, Bismuth subcitrate potassium 120 mg 4 times a day); the third group received quadruple therapy without bismuth – concomitant therapy (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day, Clarithromycin 500 mg 2 times a day and Metronidazole 500 mg 2 times a day). Diagnostics of H. pylori infection during screening and control of eradication was carried out via the fast urease biopsy sample test and urea breath test system. Control of the effectiveness of ET of the microorganism was carried out not earlier than 4 weeks after the end of the treatment. During the course of therapy, the frequency of development of side effects was assessed using a special questionnaire.
Results and discussion. The effectiveness of triple therapy was 72.8% (ITT; 95% CI of 62.17–83.54) and 78,4% (PP; 95% CI 68.19–88.72); quadruple therapy with the preparation of bismuth – 80.0% (ITT; 95% CI 70.39–89.6) and 84,8% (PP; 95% CI, 75.96–93.73); quadruple therapy without bismuth – concomitant therapy – 84.2% (ITT; 95% CI 75.54–93.02) and 92.1% (PP; 95% CI 85.43–98.94). Quadruple therapy without bismuth was reliably more effective than the classical triple therapy in the PP selection (p=0.044883). Statistical analysis showed a tendency to poorer effectiveness of ET in patients who had previously used antibiotic therapy (OR 0.4317; 95% CI 0.1776–1.049), and in individuals with a rapid metabolism genotype – CYP2C19*1/*1 (OR 0.12; 95% CI 0.005848–2.4624). The frequency of development of side effects during the use of triple therapy was 18.5% (95% CI of 9.23–27.91), when using quadruple therapy with bismuth – 20.0% (95% CI 10.39–29.6), and with the use of quadruple therapy without bismuth – concomitant therapy – 24.2% (95% CI 13.98–34.58).
Conclusion. This prospective randomized study demonstrated the high efficiency of quadruple therapy without bismuth (concomitant therapy) in the framework of eradication of H. pylori infection in Russia.
Keywords: Helicobacter pylori, eradication therapy, quadruple therapy without bismuth, concomitant therapy
Материалы и методы. Проведено проспективное рандомизированное исследование, в которое включено 210 пациентов с неосложненной H. pylori-ассоциированной язвенной болезнью желудка/двенадцатиперстной кишки. В процессе рандомизации пациенты разделены на три равные группы (n=70) в зависимости от назначаемой 10-дневной схемы эрадикационной терапии (ЭТ): первая группа получала классическую тройную схему (омепразол 20 мг 2 раза в день, амоксициллин 1000 мг 2 раза в день и кларитромицин 500 мг 2 раза в день); вторая группа получала квадротерапию с препаратами висмута (омепразол 20 мг 2 раза в день, тетрациклин 500 мг 4 раза в день, метронидазол 500 мг 3 раза в день, висмута трикалия дицитрат 120 мг 4 раза в день); третья группа получала квадротерапию без препаратов висмута (омепразол 20 мг 2 раза в день, амоксициллин 1000 мг 2 раза в день, кларитромицин 500 мг 2 раза в день и метронидазол 500 мг 2 раза в день). Диагностика инфекции H. pylori при скрининге и контроле эрадикации осуществлялась при помощи быстрого уреазного теста биоптата и дыхательной тест-системы. Контроль эффективности ЭТ микроорганизма производился не ранее чем через 4 нед после проведенного лечения. На протяжении курса терапии проводилась оценка частоты развития побочных явлений при помощи специального опросника.
Результаты и обсуждение. Эффективность тройной терапии составила 72,8% (ITT; 95% ДИ 62,17–83,54) и 78,4% (PP; 95% ДИ 68,19–88,72); квадротерапии с препаратом висмута – 80,0% (ITT; 95% ДИ 70,39–89,6) и 84,8% (PP; 95% ДИ 75,96–93,73); квадротерапии без препарата висмута – 84,2% (ITT; 95% ДИ 75,54–93,02) и 92,1% (PP; 95% ДИ 85,43–98,94). Квадротерапия без препарата висмута оказалась достоверно эффективнее классической тройной терапии в выборке PP (p=0,044883). При статистическом анализе отмечались тенденции к снижению эффективности ЭТ у пациентов, использовавших антибиотикотерапию в анамнезе (ОШ 0,4317; 95% ДИ 0,1776–1,049), и у лиц с генотипом быстрого метаболизма – CYP2C19*1/*1 (ОШ 0,12; 95% ДИ 0,005848–2,4624). Частота побочных явлений при применении тройной терапии составила 18,5% (95% ДИ 9,23–27,91), при использовании квадротерапии с препаратом висмута – 20,0% (95% ДИ 10,39–29,6), а при применении квадротерапии без препаратов висмута – 24,2% (95% ДИ 13,98–34,58).
Заключение. Проведенное проспективное рандомизированное исследование продемонстрировало высокую эффективность квадротерапии без препарата висмута в рамках эрадикации инфекции H. pylori у российского контингента пациентов.
Ключевые слова: Helicobacter pylori, эрадикационная терапия, квадротерапия без препарата висмута, одномоментная терапия.
________________________________________________
Materials and methods. A prospective randomized trial was conducted, which included 210 patients with H. pylori-associated gastric/duodenal ulcer without complications. During the process of randomization, the patients were divided into three equal groups (n=70) depending on the prescribed 10-day scheme of eradication therapy (ET): the first group received the classic triple scheme (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day and Clarithromycin 500 mg 2 times a day); the second group received quadruple therapy with bismuth drugs (Omeprazole 20 mg 2 times a day, Tetracycline 500 mg 4 times a day, Metronidazole 500 mg 3 times a day, Bismuth subcitrate potassium 120 mg 4 times a day); the third group received quadruple therapy without bismuth – concomitant therapy (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day, Clarithromycin 500 mg 2 times a day and Metronidazole 500 mg 2 times a day). Diagnostics of H. pylori infection during screening and control of eradication was carried out via the fast urease biopsy sample test and urea breath test system. Control of the effectiveness of ET of the microorganism was carried out not earlier than 4 weeks after the end of the treatment. During the course of therapy, the frequency of development of side effects was assessed using a special questionnaire.
Results and discussion. The effectiveness of triple therapy was 72.8% (ITT; 95% CI of 62.17–83.54) and 78,4% (PP; 95% CI 68.19–88.72); quadruple therapy with the preparation of bismuth – 80.0% (ITT; 95% CI 70.39–89.6) and 84,8% (PP; 95% CI, 75.96–93.73); quadruple therapy without bismuth – concomitant therapy – 84.2% (ITT; 95% CI 75.54–93.02) and 92.1% (PP; 95% CI 85.43–98.94). Quadruple therapy without bismuth was reliably more effective than the classical triple therapy in the PP selection (p=0.044883). Statistical analysis showed a tendency to poorer effectiveness of ET in patients who had previously used antibiotic therapy (OR 0.4317; 95% CI 0.1776–1.049), and in individuals with a rapid metabolism genotype – CYP2C19*1/*1 (OR 0.12; 95% CI 0.005848–2.4624). The frequency of development of side effects during the use of triple therapy was 18.5% (95% CI of 9.23–27.91), when using quadruple therapy with bismuth – 20.0% (95% CI 10.39–29.6), and with the use of quadruple therapy without bismuth – concomitant therapy – 24.2% (95% CI 13.98–34.58).
Conclusion. This prospective randomized study demonstrated the high efficiency of quadruple therapy without bismuth (concomitant therapy) in the framework of eradication of H. pylori infection in Russia.
Keywords: Helicobacter pylori, eradication therapy, quadruple therapy without bismuth, concomitant therapy
Список литературы
1. Маев И.В., Андреев Д.Н. Инфекция Helicobacter pylori и ассоциированные заболевания. М.: Ремедиум, 2018 [Maev IV, Andreev DN. Infektsiya Helicobacter pylori i assotsiirovannye zabolevaniya [Helicobacter pylori infection and associated deseases]. Moscow: Remedium, 2018 (In Russ.)].
2. Morgan DR, Crowe SE. Helicobacter pylori infection. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Eds M Feldman, LS Friedman, LJ Brandt. 10th ed. Philadelphia, 2015.
3. Маев И.В., Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Коровина Т.И. Клиническое значение инфекции Helicobacter pylori. Клиническая медицина. 2013;91(8):4-12 [Maev IV, Samsonov AA, Andreev DN, Grechushnikov VB, Korovina TI. Clinical significance of Helicobacter pylori infection. Klinicheskaya Meditsina (Moskow). 2013;91(8):4-12 (In Russ.)].
4. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252
5. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628-38. doi: 10.1038/nrgastro.2014.99
6. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-9. doi: 10.1053/j.gastro.2017.04.022
7. Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018 Apr;47(7):868-76. doi: 10.1111/apt.14561. Epub 2018 Feb 12.
8. Герман С.В., Зыкова И.Е., Модестова А.В., Ермаков Н.В. Распространенность инфекции H. pylori среди населения Москвы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2010;20(2):25-30 [German SV, Zykova IE, Modestova AV, Ermakov NV. The prevalence of H. pylori infection among the population of Moscow. Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2010;20(2):25-30 (In Russ.)].
9. Рахманин Ю.А., Зыкова И.Е., Федичкина Т.П., Соленова Л.Г., Герман С.В., Модестова А.В., Кислицин В.А. Изучение территориального раcпределения инфицированности Helicobacter pylori трудоспособного населения г. Москвы в ходе диспансеризации производственных контингентов. Гигиена и санитария. 2013;92(5):79-82 [Rakhmanin YuA, Zykova IE, Fedichkina TP, Solenova LG, German SV, Modestova AV, Kislitsin VA. The study of the territorial distribution of Helicobacter pylori infection of the working-age population of Moscow during the clinical examination of production contingents. Gigiena i Sanitariya = Hygiene and Sanitation. 2013;92(5):79-82 (In Russ.)].
10. Сварваль А.В., Ферман Р.С., Жебрун А.Б. Изучение динамики превалентности инфекции, обусловленной Helicobacter pylori, среди различных возрастных групп населения Санкт-Петербурга в 2007–2011 годах. Инфекция и иммунитет. 2012;2(4):741-6 [Svarval AV, Ferman RS, Zhebrun AB. Studying the dynamics of the prevalence of Helicobacter pylori infection among different age groups of the population of St. Petersburg in 2007–2011. Infektsiya i Immunitet = Infection and Immunity. 2012;2(4):741-6 (In Russ.)].
11. Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018 Aug;12(8):819-27. doi: 10.1080/17474124.2018.1496017
12. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288
13. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69. doi: 10.1053/j.gastro.2016.04.006
14. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
15. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018 Nov;155(5):1372-82.e17. doi: 10.1053/j.gastro.2018.07.007
16. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9 [Maev IV, Kucheryavyi YuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Therapeutic Archive. 2014;86(3):94-9 (In Russ.)].
17. Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23(3):e880-93. doi: 10.1097/MJT.0000000000000191
18. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88(1):33-45. doi: 10.1159/000350719
19. Puig I, Baylina M, Sánchez-Delgado J, López-Gongora S, Suarez D, García-Iglesias P, Muñoz N, Gisbert JP, Dacoll C, Cohen H, Calvet X. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother. 2016;71(10):2740-53. doi: 10.1093/jac/dkw220
20. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105(1):65-73. doi: 10.1038/ajg.2009.508
21. Андреев Д.Н., Маев И.В., Кучерявый Ю.А., Дичева Д.Т., Парцваниа-Виноградова Е.В. Эффективность и безопасность антихеликобактерной терапии у пациентов с сопутствующим хроническим гепатитом С. Терапевтический архив. 2016;88(4):75-81 [Andreev DN, Maev IV, Kucheryavyi YuA, Dicheva DT, Partsvania-Vinogradova EV. The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C. Therapeutic Archive. 2016;88(4):75-81 (In Russ.)]. doi: 10.17116/terarkh201688475-81
22. Самсонов А.А., Гречушников В.Б., Андреев Д.Н., Юренев Г.Л., Коровина Т.И., Лежнева Ю.А., Маев И.В. Оценка фармакоэкономических показателей лечения пациентов с заболеваниями, ассоциированными с Helicobacter pylori. Терапевтический архив. 2014;86(8):57-61 [Samsonov AA, Grechushnikov VB, Andreev DN, Iurenev GL, Korovina TI, Lezhneva YuA, Maev IV. Pharmacoeconomic evaluation of treatment in patients with Helicobacter pylori-associated diseases. Therapeutic Archive. 2014;86(8):56-61 (In Russ.)].
23. Бордин Д.С., Машарова А.А., Хомерики С.Г. Хронический гастрит: современный взгляд на старую проблему. Экспериментальная и клиническая гастроэнтерология. 2012;(5):99-106 [Bordin DS, Masharova AA, Khomeriki SG. Chronic gastritis: a modern look at the old problem. Eksperimental'naya i Klinicheskaya Gastroenterologiya. 2012;(5):99-106 (In Russ.)].
24. Андреев Д.Н., Маев И.В., Дичева Д.Т., Самсонов А.А., Парцваниа-Виноградова Е.В. Эффективность и безопасность применения ребамипида в схеме тройной эрадикационной терапии инфекции Helicobacter pylori: проспективное рандомизированное сравнительное исследование. Терапевтический архив. 2018;90(8):27-32 [Andreev DN, Maev IV, Dicheva DT, Samsonov AA, Partzvania-Vinogradova EV. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Therapeutic Archive. 2018;90(8):27-32 (In Russ.)]. doi: 10.26442/terarkh201890827-32
25. Юренев Г.Л., Парцваниа-Виноградова Е.В., Андреев Д.Н., Дичева Д.Т., Маев И.В. Оценка эффективности и безопасности гибридной схемы эрадикационной терапии инфекции Helicobacter pylori. Терапевтический архив. 2018;90(8):33-9 [Yurenev GL, Partzvania-Vinogradova EV, Andreev DN, Dicheva DT, Maiev IV. Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. Therapeutic Archive. 2018;90(8):33-9 (In Russ.)]. doi: 10.26442/terarkh201890833-39
26. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34. doi: 10.2147/CEG.S25419
27. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med. 2015;54(7):703-10. doi: 10.2169/internalmedicine.54.3442
28. Chen MJ, Chen CC, Chen YN, Chen CC, Fang YJ, Lin JT, Wu MS, Liou JM. Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2018 Oct;113(10):1444-57. doi: 10.1038/s41395-018-0217-2
29. Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637-50. doi:10.1517/14728222.2015.1073261
30. Маев И.В., Андреев Д.Н. Молекулярно-генетические предикторы резистентности к антихеликобактерной терапии. Терапевтический архив. 2017;89(8):5-12 [Maev IV, Andreev DN. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy. Therapeutic Archive. 2017;89(8):5-12 (In Russ.)]. doi: 10.17116/terarkh20178985-12
31. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30:134-40. doi: 10.5829/idosi.wasj.2014.30.mett.61
32. Horikawa C, Kodama S, Fujihara K, Hirasawa R, Yachi Y, Suzuki A, Hanyu O, Shimano H, Sone H. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014 Oct;106(1):81-7. doi: 10.1016/j.diabres.2014.07.009
33. Andreev D. Helicobacter pylori Eradication Therapy: Current Regimens. Adv Res Gastroenterol Hepatol. 2017;7(2):555710. doi: 10.19080/ARGH.2017.07.555710
34. O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA. Treatment of Helicobacter pylori infection in 2018. Helicobacter. 2018 Sep;23 Suppl 1:e12519. doi: 10.1111/hel.12519
35. Ermis F, Senocak Tasci E. Current Helicobacter pylori treatment in 2014. World J Methodol. 2015;5(2):101-7. doi: 10.5662/wjm.v5.i2.101
36. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(2):109-18. doi: 10.1111/j.1523-5378.2009.00671.x
37. Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90 [Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Therapeutic Archive. 2017;89(2):84-90 (In Russ.)]. doi: 10.17116/terarkh201789284-90
38. Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29 Suppl 4:20-4. doi: 10.1111/jgh.12769
39. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-8. doi: 10.1136/gutjnl-2015-311019
2. Morgan DR, Crowe SE. Helicobacter pylori infection. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Eds M Feldman, LS Friedman, LJ Brandt. 10th ed. Philadelphia, 2015.
3. [Maev IV, Samsonov AA, Andreev DN, Grechushnikov VB, Korovina TI. Clinical significance of Helicobacter pylori infection. Klinicheskaya Meditsina (Moskow). 2013;91(8):4-12 (In Russ.)].
4. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252
5. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628-38. doi: 10.1038/nrgastro.2014.99
6. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-9. doi: 10.1053/j.gastro.2017.04.022
7. Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018 Apr;47(7):868-76. doi: 10.1111/apt.14561. Epub 2018 Feb 12.
8. [German SV, Zykova IE, Modestova AV, Ermakov NV. The prevalence of H. pylori infection among the population of Moscow. Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2010;20(2):25-30 (In Russ.)].
9. [Rakhmanin YuA, Zykova IE, Fedichkina TP, Solenova LG, German SV, Modestova AV, Kislitsin VA. The study of the territorial distribution of Helicobacter pylori infection of the working-age population of Moscow during the clinical examination of production contingents. Gigiena i Sanitariya = Hygiene and Sanitation. 2013;92(5):79-82 (In Russ.)].
10. [Svarval AV, Ferman RS, Zhebrun AB. Studying the dynamics of the prevalence of Helicobacter pylori infection among different age groups of the population of St. Petersburg in 2007–2011. Infektsiya i Immunitet = Infection and Immunity. 2012;2(4):741-6 (In Russ.)].
11. Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018 Aug;12(8):819-27. doi: 10.1080/17474124.2018.1496017
12. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288
13. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69. doi: 10.1053/j.gastro.2016.04.006
14. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
15. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018 Nov;155(5):1372-82.e17. doi: 10.1053/j.gastro.2018.07.007
16. [Maev IV, Kucheryavyi YuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Therapeutic Archive. 2014;86(3):94-9 (In Russ.)].
17. Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23(3):e880-93. doi: 10.1097/MJT.0000000000000191
18. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88(1):33-45. doi: 10.1159/000350719
19. Puig I, Baylina M, Sánchez-Delgado J, López-Gongora S, Suarez D, García-Iglesias P, Muñoz N, Gisbert JP, Dacoll C, Cohen H, Calvet X. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother. 2016;71(10):2740-53. doi: 10.1093/jac/dkw220
20. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105(1):65-73. doi: 10.1038/ajg.2009.508
21. [Andreev DN, Maev IV, Kucheryavyi YuA, Dicheva DT, Partsvania-Vinogradova EV. The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C. Therapeutic Archive. 2016;88(4):75-81 (In Russ.)]. doi: 10.17116/terarkh201688475-81
22. [Samsonov AA, Grechushnikov VB, Andreev DN, Iurenev GL, Korovina TI, Lezhneva YuA, Maev IV. Pharmacoeconomic evaluation of treatment in patients with Helicobacter pylori-associated diseases. Therapeutic Archive. 2014;86(8):56-61 (In Russ.)].
23. [Bordin DS, Masharova AA, Khomeriki SG. Chronic gastritis: a modern look at the old problem. Eksperimental'naya i Klinicheskaya Gastroenterologiya. 2012;(5):99-106 (In Russ.)].
24. [Andreev DN, Maev IV, Dicheva DT, Samsonov AA, Partzvania-Vinogradova EV. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Therapeutic Archive. 2018;90(8):27-32 (In Russ.)]. doi: 10.26442/terarkh201890827-32
25. [Yurenev GL, Partzvania-Vinogradova EV, Andreev DN, Dicheva DT, Maiev IV. Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. Therapeutic Archive. 2018;90(8):33-9 (In Russ.)]. doi: 10.26442/terarkh201890833-39
26. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34. doi: 10.2147/CEG.S25419
27. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med. 2015;54(7):703-10. doi: 10.2169/internalmedicine.54.3442
28. Chen MJ, Chen CC, Chen YN, Chen CC, Fang YJ, Lin JT, Wu MS, Liou JM. Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2018 Oct;113(10):1444-57. doi: 10.1038/s41395-018-0217-2
29. Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637-50. doi:10.1517/14728222.2015.1073261
30. [Maev IV, Andreev DN. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy. Therapeutic Archive. 2017;89(8):5-12 (In Russ.)]. doi: 10.17116/terarkh20178985-12
31. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30:134-40. doi: 10.5829/idosi.wasj.2014.30.mett.61
32. Horikawa C, Kodama S, Fujihara K, Hirasawa R, Yachi Y, Suzuki A, Hanyu O, Shimano H, Sone H. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014 Oct;106(1):81-7. doi: 10.1016/j.diabres.2014.07.009
33. Andreev D. Helicobacter pylori Eradication Therapy: Current Regimens. Adv Res Gastroenterol Hepatol. 2017;7(2):555710. doi: 10.19080/ARGH.2017.07.555710
34. O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA. Treatment of Helicobacter pylori infection in 2018. Helicobacter. 2018 Sep;23 Suppl 1:e12519. doi: 10.1111/hel.12519
35. Ermis F, Senocak Tasci E. Current Helicobacter pylori treatment in 2014. World J Methodol. 2015;5(2):101-7. doi: 10.5662/wjm.v5.i2.101
36. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(2):109-18. doi: 10.1111/j.1523-5378.2009.00671.x
37.[Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Therapeutic Archive. 2017;89(2):84-90 (In Russ.)]. doi: 10.17116/terarkh201789284-90
38. Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29 Suppl 4:20-4. doi: 10.1111/jgh.12769
39. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-8. doi: 10.1136/gutjnl-2015-311019
2. Morgan DR, Crowe SE. Helicobacter pylori infection. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Eds M Feldman, LS Friedman, LJ Brandt. 10th ed. Philadelphia, 2015.
3. Маев И.В., Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Коровина Т.И. Клиническое значение инфекции Helicobacter pylori. Клиническая медицина. 2013;91(8):4-12 [Maev IV, Samsonov AA, Andreev DN, Grechushnikov VB, Korovina TI. Clinical significance of Helicobacter pylori infection. Klinicheskaya Meditsina (Moskow). 2013;91(8):4-12 (In Russ.)].
4. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252
5. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628-38. doi: 10.1038/nrgastro.2014.99
6. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-9. doi: 10.1053/j.gastro.2017.04.022
7. Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018 Apr;47(7):868-76. doi: 10.1111/apt.14561. Epub 2018 Feb 12.
8. Герман С.В., Зыкова И.Е., Модестова А.В., Ермаков Н.В. Распространенность инфекции H. pylori среди населения Москвы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2010;20(2):25-30 [German SV, Zykova IE, Modestova AV, Ermakov NV. The prevalence of H. pylori infection among the population of Moscow. Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2010;20(2):25-30 (In Russ.)].
9. Рахманин Ю.А., Зыкова И.Е., Федичкина Т.П., Соленова Л.Г., Герман С.В., Модестова А.В., Кислицин В.А. Изучение территориального раcпределения инфицированности Helicobacter pylori трудоспособного населения г. Москвы в ходе диспансеризации производственных контингентов. Гигиена и санитария. 2013;92(5):79-82 [Rakhmanin YuA, Zykova IE, Fedichkina TP, Solenova LG, German SV, Modestova AV, Kislitsin VA. The study of the territorial distribution of Helicobacter pylori infection of the working-age population of Moscow during the clinical examination of production contingents. Gigiena i Sanitariya = Hygiene and Sanitation. 2013;92(5):79-82 (In Russ.)].
10. Сварваль А.В., Ферман Р.С., Жебрун А.Б. Изучение динамики превалентности инфекции, обусловленной Helicobacter pylori, среди различных возрастных групп населения Санкт-Петербурга в 2007–2011 годах. Инфекция и иммунитет. 2012;2(4):741-6 [Svarval AV, Ferman RS, Zhebrun AB. Studying the dynamics of the prevalence of Helicobacter pylori infection among different age groups of the population of St. Petersburg in 2007–2011. Infektsiya i Immunitet = Infection and Immunity. 2012;2(4):741-6 (In Russ.)].
11. Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018 Aug;12(8):819-27. doi: 10.1080/17474124.2018.1496017
12. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288
13. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69. doi: 10.1053/j.gastro.2016.04.006
14. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
15. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018 Nov;155(5):1372-82.e17. doi: 10.1053/j.gastro.2018.07.007
16. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9 [Maev IV, Kucheryavyi YuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Therapeutic Archive. 2014;86(3):94-9 (In Russ.)].
17. Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23(3):e880-93. doi: 10.1097/MJT.0000000000000191
18. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88(1):33-45. doi: 10.1159/000350719
19. Puig I, Baylina M, Sánchez-Delgado J, López-Gongora S, Suarez D, García-Iglesias P, Muñoz N, Gisbert JP, Dacoll C, Cohen H, Calvet X. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother. 2016;71(10):2740-53. doi: 10.1093/jac/dkw220
20. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105(1):65-73. doi: 10.1038/ajg.2009.508
21. Андреев Д.Н., Маев И.В., Кучерявый Ю.А., Дичева Д.Т., Парцваниа-Виноградова Е.В. Эффективность и безопасность антихеликобактерной терапии у пациентов с сопутствующим хроническим гепатитом С. Терапевтический архив. 2016;88(4):75-81 [Andreev DN, Maev IV, Kucheryavyi YuA, Dicheva DT, Partsvania-Vinogradova EV. The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C. Therapeutic Archive. 2016;88(4):75-81 (In Russ.)]. doi: 10.17116/terarkh201688475-81
22. Самсонов А.А., Гречушников В.Б., Андреев Д.Н., Юренев Г.Л., Коровина Т.И., Лежнева Ю.А., Маев И.В. Оценка фармакоэкономических показателей лечения пациентов с заболеваниями, ассоциированными с Helicobacter pylori. Терапевтический архив. 2014;86(8):57-61 [Samsonov AA, Grechushnikov VB, Andreev DN, Iurenev GL, Korovina TI, Lezhneva YuA, Maev IV. Pharmacoeconomic evaluation of treatment in patients with Helicobacter pylori-associated diseases. Therapeutic Archive. 2014;86(8):56-61 (In Russ.)].
23. Бордин Д.С., Машарова А.А., Хомерики С.Г. Хронический гастрит: современный взгляд на старую проблему. Экспериментальная и клиническая гастроэнтерология. 2012;(5):99-106 [Bordin DS, Masharova AA, Khomeriki SG. Chronic gastritis: a modern look at the old problem. Eksperimental'naya i Klinicheskaya Gastroenterologiya. 2012;(5):99-106 (In Russ.)].
24. Андреев Д.Н., Маев И.В., Дичева Д.Т., Самсонов А.А., Парцваниа-Виноградова Е.В. Эффективность и безопасность применения ребамипида в схеме тройной эрадикационной терапии инфекции Helicobacter pylori: проспективное рандомизированное сравнительное исследование. Терапевтический архив. 2018;90(8):27-32 [Andreev DN, Maev IV, Dicheva DT, Samsonov AA, Partzvania-Vinogradova EV. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Therapeutic Archive. 2018;90(8):27-32 (In Russ.)]. doi: 10.26442/terarkh201890827-32
25. Юренев Г.Л., Парцваниа-Виноградова Е.В., Андреев Д.Н., Дичева Д.Т., Маев И.В. Оценка эффективности и безопасности гибридной схемы эрадикационной терапии инфекции Helicobacter pylori. Терапевтический архив. 2018;90(8):33-9 [Yurenev GL, Partzvania-Vinogradova EV, Andreev DN, Dicheva DT, Maiev IV. Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. Therapeutic Archive. 2018;90(8):33-9 (In Russ.)]. doi: 10.26442/terarkh201890833-39
26. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34. doi: 10.2147/CEG.S25419
27. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med. 2015;54(7):703-10. doi: 10.2169/internalmedicine.54.3442
28. Chen MJ, Chen CC, Chen YN, Chen CC, Fang YJ, Lin JT, Wu MS, Liou JM. Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2018 Oct;113(10):1444-57. doi: 10.1038/s41395-018-0217-2
29. Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637-50. doi:10.1517/14728222.2015.1073261
30. Маев И.В., Андреев Д.Н. Молекулярно-генетические предикторы резистентности к антихеликобактерной терапии. Терапевтический архив. 2017;89(8):5-12 [Maev IV, Andreev DN. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy. Therapeutic Archive. 2017;89(8):5-12 (In Russ.)]. doi: 10.17116/terarkh20178985-12
31. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30:134-40. doi: 10.5829/idosi.wasj.2014.30.mett.61
32. Horikawa C, Kodama S, Fujihara K, Hirasawa R, Yachi Y, Suzuki A, Hanyu O, Shimano H, Sone H. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014 Oct;106(1):81-7. doi: 10.1016/j.diabres.2014.07.009
33. Andreev D. Helicobacter pylori Eradication Therapy: Current Regimens. Adv Res Gastroenterol Hepatol. 2017;7(2):555710. doi: 10.19080/ARGH.2017.07.555710
34. O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA. Treatment of Helicobacter pylori infection in 2018. Helicobacter. 2018 Sep;23 Suppl 1:e12519. doi: 10.1111/hel.12519
35. Ermis F, Senocak Tasci E. Current Helicobacter pylori treatment in 2014. World J Methodol. 2015;5(2):101-7. doi: 10.5662/wjm.v5.i2.101
36. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(2):109-18. doi: 10.1111/j.1523-5378.2009.00671.x
37. Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90 [Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Therapeutic Archive. 2017;89(2):84-90 (In Russ.)]. doi: 10.17116/terarkh201789284-90
38. Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29 Suppl 4:20-4. doi: 10.1111/jgh.12769
39. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-8. doi: 10.1136/gutjnl-2015-311019
________________________________________________
2. Morgan DR, Crowe SE. Helicobacter pylori infection. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Eds M Feldman, LS Friedman, LJ Brandt. 10th ed. Philadelphia, 2015.
3. [Maev IV, Samsonov AA, Andreev DN, Grechushnikov VB, Korovina TI. Clinical significance of Helicobacter pylori infection. Klinicheskaya Meditsina (Moskow). 2013;91(8):4-12 (In Russ.)].
4. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252
5. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628-38. doi: 10.1038/nrgastro.2014.99
6. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-9. doi: 10.1053/j.gastro.2017.04.022
7. Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018 Apr;47(7):868-76. doi: 10.1111/apt.14561. Epub 2018 Feb 12.
8. [German SV, Zykova IE, Modestova AV, Ermakov NV. The prevalence of H. pylori infection among the population of Moscow. Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2010;20(2):25-30 (In Russ.)].
9. [Rakhmanin YuA, Zykova IE, Fedichkina TP, Solenova LG, German SV, Modestova AV, Kislitsin VA. The study of the territorial distribution of Helicobacter pylori infection of the working-age population of Moscow during the clinical examination of production contingents. Gigiena i Sanitariya = Hygiene and Sanitation. 2013;92(5):79-82 (In Russ.)].
10. [Svarval AV, Ferman RS, Zhebrun AB. Studying the dynamics of the prevalence of Helicobacter pylori infection among different age groups of the population of St. Petersburg in 2007–2011. Infektsiya i Immunitet = Infection and Immunity. 2012;2(4):741-6 (In Russ.)].
11. Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018 Aug;12(8):819-27. doi: 10.1080/17474124.2018.1496017
12. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288
13. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69. doi: 10.1053/j.gastro.2016.04.006
14. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
15. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018 Nov;155(5):1372-82.e17. doi: 10.1053/j.gastro.2018.07.007
16. [Maev IV, Kucheryavyi YuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Therapeutic Archive. 2014;86(3):94-9 (In Russ.)].
17. Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23(3):e880-93. doi: 10.1097/MJT.0000000000000191
18. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88(1):33-45. doi: 10.1159/000350719
19. Puig I, Baylina M, Sánchez-Delgado J, López-Gongora S, Suarez D, García-Iglesias P, Muñoz N, Gisbert JP, Dacoll C, Cohen H, Calvet X. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother. 2016;71(10):2740-53. doi: 10.1093/jac/dkw220
20. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105(1):65-73. doi: 10.1038/ajg.2009.508
21. [Andreev DN, Maev IV, Kucheryavyi YuA, Dicheva DT, Partsvania-Vinogradova EV. The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C. Therapeutic Archive. 2016;88(4):75-81 (In Russ.)]. doi: 10.17116/terarkh201688475-81
22. [Samsonov AA, Grechushnikov VB, Andreev DN, Iurenev GL, Korovina TI, Lezhneva YuA, Maev IV. Pharmacoeconomic evaluation of treatment in patients with Helicobacter pylori-associated diseases. Therapeutic Archive. 2014;86(8):56-61 (In Russ.)].
23. [Bordin DS, Masharova AA, Khomeriki SG. Chronic gastritis: a modern look at the old problem. Eksperimental'naya i Klinicheskaya Gastroenterologiya. 2012;(5):99-106 (In Russ.)].
24. [Andreev DN, Maev IV, Dicheva DT, Samsonov AA, Partzvania-Vinogradova EV. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Therapeutic Archive. 2018;90(8):27-32 (In Russ.)]. doi: 10.26442/terarkh201890827-32
25. [Yurenev GL, Partzvania-Vinogradova EV, Andreev DN, Dicheva DT, Maiev IV. Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. Therapeutic Archive. 2018;90(8):33-9 (In Russ.)]. doi: 10.26442/terarkh201890833-39
26. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34. doi: 10.2147/CEG.S25419
27. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med. 2015;54(7):703-10. doi: 10.2169/internalmedicine.54.3442
28. Chen MJ, Chen CC, Chen YN, Chen CC, Fang YJ, Lin JT, Wu MS, Liou JM. Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2018 Oct;113(10):1444-57. doi: 10.1038/s41395-018-0217-2
29. Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637-50. doi:10.1517/14728222.2015.1073261
30. [Maev IV, Andreev DN. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy. Therapeutic Archive. 2017;89(8):5-12 (In Russ.)]. doi: 10.17116/terarkh20178985-12
31. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30:134-40. doi: 10.5829/idosi.wasj.2014.30.mett.61
32. Horikawa C, Kodama S, Fujihara K, Hirasawa R, Yachi Y, Suzuki A, Hanyu O, Shimano H, Sone H. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014 Oct;106(1):81-7. doi: 10.1016/j.diabres.2014.07.009
33. Andreev D. Helicobacter pylori Eradication Therapy: Current Regimens. Adv Res Gastroenterol Hepatol. 2017;7(2):555710. doi: 10.19080/ARGH.2017.07.555710
34. O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA. Treatment of Helicobacter pylori infection in 2018. Helicobacter. 2018 Sep;23 Suppl 1:e12519. doi: 10.1111/hel.12519
35. Ermis F, Senocak Tasci E. Current Helicobacter pylori treatment in 2014. World J Methodol. 2015;5(2):101-7. doi: 10.5662/wjm.v5.i2.101
36. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(2):109-18. doi: 10.1111/j.1523-5378.2009.00671.x
37.[Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Therapeutic Archive. 2017;89(2):84-90 (In Russ.)]. doi: 10.17116/terarkh201789284-90
38. Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29 Suppl 4:20-4. doi: 10.1111/jgh.12769
39. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-8. doi: 10.1136/gutjnl-2015-311019
Авторы
А.М. Велиев, И.В. Маев, Д.Н. Андреев, Д.Т. Дичева, А.В. Заборовский, Е.Г. Лобанова, Л.Г. Бектемирова
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
________________________________________________
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.